Search Within

Saad Zafar Usmani

Formats
  1. Meeting Abstract (214)
  2. Journal Article (69)
  3. Review (15)
  4. Research Letter (10)
  5. Correspondence (4)
  6. Editorial (4)
  7. Guidelines (2)
  8. Book Section (1)
Groups
  1. Hematologic Malignancies, Division of (158)
  2. Department of Medicine (155)
  3. Center for Hematologic Malignancies (151)
  4. Graduate Medical Education (140)
  5. Myeloma (140)
  6. GME, Medicine (131)

More Groups

People
  1. Alexander Lesokhin (121)
  2. Kylee Maclachlan (117)
  3. Sham Mailankody (106)
  4. Urvi Shah (105)
  5. Carlyn Rose Tan (100)
  6. Neha Korde (97)

More People

Years
  1. 2025 (20)
  2. 2024 (93)
  3. 2023 (123)
  4. 2022 (83)
Publications
  1. Blood (104)
  2. Clinical Lymphoma, Myeloma and Leukemia (80)
  3. Journal of Clinical Oncology (30)
  4. Blood Cancer Journal (14)
  5. Blood Advances (13)
  6. Oncology Research and Treatment (7)

More Publications

Publishers
  1. American Society of Hematology (117)
  2. Elsevier Inc. (92)
  3. American Society of Clinical Oncology (30)
  4. Nature Publishing Group (21)
  5. Elsevier Science, Inc. (10)
  6. S. Karger AG (7)

More Publishers

Results (319)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real-world data
    Journal Article

    Biran, N.; Dhakal, B.; Niesvizky, R.; Lentzsch, S.; Bhutani, D.; McKay, J. T.; Vesole, D. H.; Nooka, A.; Paul, B.; Hari, P. N.; more...
    British Journal of Haematology (2025)

    Fulltext@MSK | Save
  • Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma
    Review

    Tix, T.; Alhomoud, M.; Shouval, R.; Iacoboni, G.; Cliff, E. R. S.; Hansen, D. K.; Usmani, S. Z.; Salles, G.; Perales, M. A.; Cordas dos Santos, D. M.; more...
    Molecular Therapy (2025)

    Fulltext@MSK | Save
  • Barriers to chimeric antigen receptor T-cell therapy
    Research Letter

    Valtis, Y. K.; Chin, K. K.; Nemirovsky, D.; Devlin, S. M.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; more...
    JAMA Oncology (2025)

    Fulltext@MSK | Save
  • Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone: An analysis of patient-reported outcomes from the phase 3 CANDOR trial
    Journal Article

    Weisel, K.; Mateos, M. V.; Landgren, O.; Leleu, X.; Quach, H.; Bennett, L.; Talpes, M.; Majer, I.; Patel, S.; Usmani, S. Z.
    Clinical Lymphoma, Myeloma and Leukemia (2025)

    Fulltext@MSK | Save
  • Modeling MRD changes in myeloma to understand treatment effects, predict outcomes, and investigate curative potential
    Journal Article

    Gregory, W. M.; Prior, T. J.; Blake Bartlett, J.; Sonneveld, P.; Dimopoulos, M. A.; Moreau, P.; Usmani, S.; Facon, T.
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: An International Myeloma Foundation immunotherapy database real-world analysis: IMMUNOTHERAPY
    Correspondence

    Mian, H.; Martin, T. G.; Pond, G. R.; Asoori, S.; Popat, R.; Kastritis, E.; Martinez-Lopez, J.; Abdallah, N.; Chhabra, S.; Parrondo, R.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: The randomized phase 3 CEPHEUS trial
    Journal Article

    Usmani, S. Z.; Facon, T.; Hungria, V.; Bahlis, N. J.; Venner, C. P.; Braunstein, M.; Pour, L.; Martí, J. M.; Basu, S.; Cohen, Y. C.; more...
    Nature Medicine (2025)

    Fulltext@MSK | Save
  • Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes: MULTIPLE MYELOMA, GAMMOPATHIES
    Journal Article

    Facon, T.; Moreau, P.; Weisel, K.; Goldschmidt, H.; Usmani, S. Z.; Chari, A.; Plesner, T.; Orlowski, R. Z.; Bahlis, N.; Basu, S.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • Sustained improvement in health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone: MAIA final analysis of patient-reported outcomes
    Journal Article

    Perrot, A.; Facon, T.; Plesner, T.; Usmani, S. Z.; Kumar, S.; Bahlis, N. J.; Hulin, C.; Orlowski, R. Z.; Nahi, H.; Mollee, P.; more...
    European Journal of Haematology (2025)

    Fulltext@MSK | Save
  • Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): An International Myeloma Working Group Study
    Journal Article

    Tan, C. R.; Asoori, S.; Huang, C. Y.; Brunaldi, L.; Popat, R.; Kastritis, E.; Martinez-Lopez, J.; Bansal, R.; Silva Corraes, A. D. M.; Chhabra, S.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save